These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25793299)

  • 1. Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
    Kim JY; Shin E; Kim JW; Lee HS; Lee DW; Kim SH; Lee JO; Kim YJ; Kim JH; Bang SM; Ahn SH; Park DJ; Lee JS; Lee JS; Kim HH; Lee KW
    PLoS One; 2015; 10(3):e0120324. PubMed ID: 25793299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study).
    Mori T; Ohue M; Takii Y; Hashizume T; Kato T; Kotake K; Sato T; Tango T
    Oncol Rep; 2013 Feb; 29(2):437-44. PubMed ID: 23232805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.
    Sasako M; Terashima M; Ichikawa W; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H
    Gastric Cancer; 2015 Jul; 18(3):538-48. PubMed ID: 25112781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral gene expression of 5-fluorouracil pharmacokinetics-related enzymes in stage I and II non-small cell lung cancer patients treated with uracil-tegafur after surgery: a prospective multi-institutional study in Japan.
    Eguchi K; Oyama T; Tajima A; Abiko T; Sawafuji M; Horio H; Hashizume T; Matsutani N; Kato R; Nakayama M; Kawamura M; Kobayashi K
    Lung Cancer; 2015 Jan; 87(1):53-8. PubMed ID: 25468199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer.
    Jeung HC; Rha SY; Shin SJ; Lim SJ; Roh JK; Noh SH; Chung HC
    Anticancer Drugs; 2011 Sep; 22(8):801-10. PubMed ID: 21572321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1.
    Ichikawa W; Takahashi T; Suto K; Shirota Y; Nihei Z; Shimizu M; Sasaki Y; Hirayama R
    Int J Cancer; 2006 Oct; 119(8):1927-33. PubMed ID: 16736497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
    Sakurai Y; Kamoshida S; Furuta S; Sunagawa R; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1147-55. PubMed ID: 18633253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
    Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
    Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
    Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
    Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.
    Miyamoto S; Boku N; Ohtsu A; Yoshida S; Ochiai A; Okabe H; Fukushima M
    Int J Oncol; 2000 Oct; 17(4):653-8. PubMed ID: 10995874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion.
    Uchida K; Hayashi K; Kuramochi H; Takasaki K
    Int J Oncol; 2001 Aug; 19(2):341-6. PubMed ID: 11445849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
    Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C
    Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
    Kuramochi H; Hayashi K; Uchida K; Nakajima G; Hatori T; Danenberg KD; Danenberg PV; Yamamoto M
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):85-9. PubMed ID: 18309485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer.
    Kamoshida S; Shiogama K; Shimomura R; Inada K; Sakurai Y; Ochiai M; Matuoka H; Maeda K; Tsutsumi Y
    Oncol Rep; 2005 Nov; 14(5):1223-30. PubMed ID: 16211289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1.
    Harada K; Kawashima Y; Yoshida H; Sato M
    Oncol Rep; 2006 Jun; 15(6):1417-23. PubMed ID: 16685374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
    He MM; Zhang DS; Wang F; Wang ZX; Yuan SQ; Wang ZQ; Luo HY; Ren C; Qiu MZ; Jin Y; Wang DS; Chen DL; Zeng ZL; Li YH; He YY; Hao YT; Guo P; Wang FH; Zeng YX; Xu RH
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):69-79. PubMed ID: 27913881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quantitative evaluation of the determinant proteins for S-1 responsiveness in a biopsy specimen assists in patient selection to neoadjuvant therapy in cases of advanced gastric cancer.
    Hashiguchi K; Kitajima Y; Kai K; Hiraki M; Nakamura J; Tokunaga O; Noshiro H; Miyazaki K
    Int J Oncol; 2010 Aug; 37(2):257-64. PubMed ID: 20596652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
    Ito S; Ohashi Y; Sasako M
    BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
    Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
    Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.